Patents by Inventor Troels Koch

Troels Koch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiophosphoramidites
    Patent number: 11597926
    Abstract: The present invention relates to a compound of formula (II) or (IIb) Wherein X, Y, Rx, Ry, R5 and Nu are as defined in the description and in the claims. The compound of formula (II) can be used in the manufacture of oligonucleotides.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 7, 2023
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Konrad Bleicher, Joerg Duschmalé, Martina Brigitte Duschmalé, Henrik Frydenlund Hansen, Troels Koch, Meiling Li, Adrian Schaeublin, Xi Shu, Yong Wu
  • OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
    Publication number: 20230002762
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicement.
    Type: Application
    Filed: April 14, 2022
    Publication date: January 5, 2023
    Applicant: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Konrad Bleicher, Henrik Frydenlund HANSEN, Troels KOCH, Jesper WORM, Adrian SCHAEUBLIN, Erik FUNDER, Joerg DUSCHMALÉ, Lars JOENSON, Meiling LI, Martina Brigitte DUSCHMALÉ, Yong WU, Xi SHU
  • NEOANTIGEN ENGINEERING USING SPLICE MODULATING COMPOUNDS
    Publication number: 20220160870
    Abstract: The invention relates to the field of immunotherapy and vaccine treatment of diseased cells via enhancing the immune response to the diseased cells. In the context of the present invention this is done by engineering neo-antigens in cells via oligonucleotide mediated production of aberrant RNA transcripts which, when transcribed in the cell, result in the generation or increased expression of aberrant polypeptides. Extracellular display of these polypeptides, of peptide fragments derived provides antigen epitopes (neoantigen) for detection by the immune system.
    Type: Application
    Filed: August 28, 2019
    Publication date: May 26, 2022
    Inventors: Troels Koch, Kamille Dumong Erichsen, Mads Jensen, Jonas Vikesaa, Lars Joenson, Klaus Jensen, Gianluigi Lichinchi
  • OLIGONUCLEOTIDES COMPRISING A PHOSPHOROTRITHIOATE INTERNUCLEOSIDE LINKAGE
    Publication number: 20210292358
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorotrithioa to internucleoside linkage of formula (I), wherein (A1), (A2) and R are as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicament.
    Type: Application
    Filed: July 30, 2019
    Publication date: September 23, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Konrad Bleicher, Troels KOCH, Adrian SCHAEUBLIN, Joerg Jakob Andreas DUSCHMALE, Martina Brigitte DUSCHMALE, Meiling LI, Erich KOLLER
  • OLIGONUCLEOTIDES COMPRISING A PHOSPHOROTRITHIOATE INTERNUCLEOSIDE LINKAGE
    Publication number: 20210221837
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorotrithioate internucleoside linkage of formula (I) as defined herein. The oligonucleotide of the invention can be used as a medicament.
    Type: Application
    Filed: July 29, 2019
    Publication date: July 22, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Konrad BLEICHER, Joerg Jakob Andreas DUSCHMALÉ, Martina Brigitte DUSCHMALÉ, Troels KOCH, Erich KOLLER, Meiling LI, Adrian SCHAEUBLIN
  • NOVEL THIOPHOSPHORAMIDITES
    Publication number: 20210115438
    Abstract: The present invention relates to a compound of formula (II) or (IIb) Wherein X, Y, Rx, Ry, R5 and Nu are as defined in the description and in the claims. The compound of formula (II) can be used in the manufacture of oligonucleotides.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 22, 2021
    Applicant: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Konrad BLEICHER, Joerg DUSCHMALÉ, Martina Brigitte DUSCHMALÉ, Henrik Frydenlund HANSEN, Troels KOCH, Meiling LI, Adrian SCHAEUBLIN, Xi SHU, Yong WU
  • OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
    Publication number: 20200339982
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicament.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 29, 2020
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Konrad BLEICHER, Henrik Frydenlund HANSEN, Troels KOCH, Jesper WORM, Adrian SCHAEUBLIN, Erik FUNDER, Joerg DUSCHMALÉ, Lars JOENSON, Meiling LI, Martina Brigitte DUSCHMALÉ, Yong WU, Xi SHU
  • Chiral library screen
    Patent number: 10815481
    Abstract: The invention relates to a method of identifying stereodefined phosphorothioate oligonucleotide variants with reduced toxicity by creating and screening libraries of stereodefined chiral phosphorothioate variants for compounds with reduced toxicity, either in vitro or in vivo.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: October 27, 2020
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Henrik Frydenlund Hansen, Troels Koch, Sabine Sewing, Nanna Albaek, Peter Hagedorn, Jacob Ravn, Christoph Rosenbohm, Annie Moisan, Marcel Gubler
  • GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
    Publication number: 20200332289
    Abstract: The present invention relates to a gapmer oligonucleotide comprising at phosphorodithioate internucleoside linkage of formula (I) as defined in the description and in the claims. The oligonucleotide of the invention can be used as a medicament.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 22, 2020
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Konrad BLEICHER, Joerg DUSCHMALÉ, Martina Brigitte DUSCHMALÉ, Henrik Frydenlund HANSEN, Erik FUNDER, Troels KOCH, Meiling LI, Adrian SCHAEUBLIN, Xi SHU, Yong WU
  • STEREODEFINED SUB-MOTIF OPTIMISATION METHODS
    Publication number: 20200318103
    Abstract: The present invention relates to methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides. The methods allow for the efficient identification of stereodefined variants with improved properties, such as enhanced in vitro or in vivo activity, enhanced efficacy, enhanced specific activity, reduced toxicity, altered biodistribution, enhanced cellular or tissue uptake, and/or enhanced target specificity (reduced off-target effects).
    Type: Application
    Filed: April 13, 2020
    Publication date: October 8, 2020
    Inventors: Konrad Bleicher, Henrik Frydenlund Hansen, Troels Koch, Nanna Albaek, Erik Daa Funder
  • ANTISENSE DESIGN
    Publication number: 20180237777
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Application
    Filed: January 5, 2018
    Publication date: August 23, 2018
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
  • ANTISENSE DESIGN
    Publication number: 20180237778
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Application
    Filed: January 5, 2018
    Publication date: August 23, 2018
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
  • Antisense design
    Patent number: 9994850
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 12, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
  • Stereospecific Phosphorothioate LNA
    Publication number: 20180112217
    Abstract: The present invention provides stereodefined phosphorothioate LNA oligonucleotide, comprising at least one stereodefined phosphorothioate linkage between a LNA nucleoside and a subsequent (3?) nucleoside.
    Type: Application
    Filed: November 18, 2015
    Publication date: April 26, 2018
    Inventors: Henrik Frydenlund Hansen, Troels Koch, Nanna Albaek, Jacob Ravn, Christoph Rosenbohm, Peter Hagedorn
  • Antisense design
    Patent number: 9951333
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: April 24, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Charlotte Albaek Thrue, Majken Westergaard, Christoph Rosenbohm
  • Antisense design
    Patent number: 9890383
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: February 13, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
  • LNA Gapmer Oligonucleotides Comprising Chiral Phosphorothioate Linkages
    Publication number: 20180016575
    Abstract: The present relates to LNA gapmer antisense oligonucleotides which comprise stereodefined phosphoramidite linkages. The use of stereodefined phosphoramidite linkages in LNA gapmers has been found to provide enhanced RNaseH activity, and modifying stereospecificity enables the reduced toxicity, altered biodistribution, and enhanced mismatch discrimination.
    Type: Application
    Filed: November 18, 2015
    Publication date: January 18, 2018
    Inventors: Henrik Frydenlund Hansen, Troels Koch, Nanna Albaek, Jacob Ravn, Christoph Rosenbohm, Peter Hagedorn
  • ANTISENSE DESIGN
    Publication number: 20170342413
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Application
    Filed: June 9, 2017
    Publication date: November 30, 2017
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
  • ANTISENSE DESIGN
    Publication number: 20170342412
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Application
    Filed: June 9, 2017
    Publication date: November 30, 2017
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
  • Chiral Library Screen
    Publication number: 20170335323
    Abstract: The invention relates to a method of identifying stereodefined phosphorothioate oligonucleotide variants with reduced toxicity by creating and screening libraries of stereodefined chiral phosphorothioate variants for compounds with reduced toxicity, either in vitro or in vivo.
    Type: Application
    Filed: December 16, 2015
    Publication date: November 23, 2017
    Inventors: Henrik Frydenlund Hansen, Troels Koch, Sabine Sewing, Nanna Albaek, Peter Hagedorn, Jacob Ravn, Christoph Rosenbohm, Annie Moisan, Marcel Gubler